Innovation in oncology is accelerating, but the evidence needed to guide treatment decision-making often lags behind. This is particularly evident in metastatic castration-resistant prostate cancer (mCRPC).
In mCRPC, multiple PARP inhibitors combined with androgen receptor pathway inhibitors are now available, including:
- Talazoparib plus enzalutamide
- Olaparib plus abiraterone acetate
- Niraparib plus abiraterone acetate
However, the absence of head-to-head trials leaves clinicians, payers, and health technology assessment bodies navigating a complex landscape with limited direct comparative evidence.
How the Analysis was Conducted
To address this gap, EVERSANA’s Value and Evidence team (Anja Haltner, Di Wang, Stefanie Paganelli, and Imtiaz Samjoo) conducted a matching-adjusted indirect comparison (MAIC). This approach:
- Utilizes individual patient data from the phase 3 TALAPRO-2 trial
- Incorporates published results from the phase 3 PROpel and MAGNITUDE trials
- Adjusts forcross-trial differences in baseline characteristics
The goal: enable more balanced and meaningful comparisons of survival outcomes across therapies and patient populations.
Key Findings
The findings showed that talazoparib plus enzalutamide was associated with improved radiographic progression-free survival compared with olaparib plus abiraterone acetate, with similar overall survival.
Compared with niraparib plus abiraterone acetate, talazoparib plus enzalutamide demonstrated improvements in both progression-free and overall survival across multiple patient populations.
These results suggested a potential clinical benefit for talazoparib plus enzalutamide across a range of patients with mCRPC. Taken together, these findings suggest a potential clinical advantage for talazoparib plus enzalutamide across a broad range of patients with mCRPC and highlight that treatment differentiation is possible, even in the absence of direct trials, when rigorous methodologies are applied.
What This Means for Decision-Makers
As innovation accelerates, this analysis highlights the importance of advanced evidence synthesis methods in translating data into actionable insights and supporting more confident decisions across clinical and payer settings.
Explore the methodology and results in detail.
Author
Anja brings over 10 years of academic and industry experience in applied statistical analyses. Anja’s research focuses on population-adjusted indirect treatment comparisons including matching-adjusted indirect comparisons, simulated treatment comparisons, and propensity score matching and…
Di is a Principal Statistician on Value & Evidence team at EVERSANA, with extensive experience in conducting indirect treatment comparisons. Since joining EVRSANA in 2022, Di has been involved in the implementation of various…
Stefanie is a Manager in the Evidence Synthesis group at EVERSANA. Stefanie brings over five years of experience supporting systematic and targeted literature reviews across a range of disease areas, including prostate cancer, multiple…
As Vice President of the Value & Evidence team at EVERSANA®, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modelling, to support reimbursement and market access for pharmaceuticals. Imtiaz…